Skip to main content
Clinical Trials/NCT06318221
NCT06318221
Completed
Not Applicable

A Randomized Clinical Trial With Perioperative Immunonutrition Support on Anthropometric, Clinical and Biochemical Parameters of Head and Neck Cancer Patients Undergoing Surgery

TC Erciyes University1 site in 1 country34 target enrollmentMay 1, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Head and Neck Cancer
Sponsor
TC Erciyes University
Enrollment
34
Locations
1
Primary Endpoint
Albumin
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

A prospective randomized controlled study compared the effects of perioperative immunonutrition and standard enteral nutrition (EN) on postoperative short-term outcomes of patients with head and neck (HNC).

Five days before surgery and the postoperative day 10, immunonutrition support was given to the intervention group (n=17), and standard EN support was given to the control group (n=17). Body analyses were made, food consumption records were taken, NRS-2002 and quality of life scales were applied, and biochemical parameters were recorded.

Registry
clinicaltrials.gov
Start Date
May 1, 2019
End Date
February 1, 2021
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Eda Başmısırlı

Asst. Prof. Dr.

TC Erciyes University

Eligibility Criteria

Inclusion Criteria

  • Clinical diagnosis of squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx who will undergo surgery,
  • who agree to receive standard EN or immunonutrition before surgery,
  • those between the ages of 18-75,
  • those with normal hematopoietic (absolute neutrophil count \>1.8x109/L, hemoglobin level ≥9 g/dL) hepatic and renal function

Exclusion Criteria

  • Patients receiving neoadjuvant chemotherapy or radiotherapy to the head and neck region;
  • Received EN support before the study
  • have an active infection, any autoimmune, renal or hepatic disease, malabsorption, type 1 diabetes or mental illness
  • taking vitamin-mineral supplements and immunosuppressive treatment,
  • Morbidly obese (BMI ≥40 kg/m2), HIV positive, pregnant and breastfeeding individuals

Outcomes

Primary Outcomes

Albumin

Time Frame: 40 days

g/dL

Nutrition Risk Screening 2002

Time Frame: 40 days

A total score of ≥3 indicates that the patient is at nutritional risk

Body weight

Time Frame: 40 days

Kg

Body weight loss

Time Frame: 40 days

Kg

Body mass index

Time Frame: 40 days

kg/m2

Resting metabolic rate

Time Frame: 40 days

kcal

The EORTC Core Quality of Life questionnaire-30 (EORTC QLQ-C30)

Time Frame: 40 days

1. Estimate the average of the items that contribute to the scale; this is the raw score. 2. Use a linear transformation to standardise the raw score, so that scores range from 0 to 100; a higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms.

The EORTC Quality of life - Head and Neck Cancer Module (EORTC QLQ-H & N35)

Time Frame: 40 days

The head \& neck cancer module incorporates seven multi-item scales that assess pain, swallowing, senses (taste and smell), speech, social eating, social contact and sexuality. There are also eleven single items. For all items and scales, high scores indicate more problems (i.e. there are no function scales in which high scores would mean better functioning).

C-reactive protein

Time Frame: 40 days

mg/L

Prealbumin

Time Frame: 40 days

mg/dL

Secondary Outcomes

  • Complication development status(40 days)
  • Length of hospital stay(40 days)

Study Sites (1)

Loading locations...

Similar Trials